Novartis

Expands Novartis Oncology radioligand pipeline with exclusive worldwide rights to develop and commercialise therapeutic…

Novartis last year agreed to license two of Molecular Partners’ antiviral drugs that it hopes to use to treat COVID-19 patients

The drug regulator cited unresolved facility inspection issues for denying approval

Novartis gains full rights to Cadent’s NMDAr allosteric modulator program, pre-clinical programs and clinical stage movement…

They assured that they will work towards developing innovations to fight the COVID-19 pandemic, ensuring their timely availability…

The financial details of the transaction have not been revealed but the facility in Germany’s Marburg will be converted to be…

Johnson & Johnson maintained its top position with MCap growth of 7.2 per cent on a QoQ basis

The analysis evaluated the efficacy and tolerability of inclisiran on top of a maximally tolerated dose of statins, in two studies…

Ofatumumab was first approved by the FDA in 2009 for the treatment of chronic lymphocytic leukaemia (CLL)

The one-a-day oral drug is viewed as a potential a rival to Spinraza, which is administered every four months via spinal infusion